DXPE Stock DD DXP Enterprises, Inc. 09/12/2014 13:52:18

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2014 at 2:52 PM

DXPE DXP Enterprises, Inc. $DXPE Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=DXPE&...mp;yt0=Go!

Last Updated: 09/12/2014 13:52:14

Current Price and Quotes
Last Price 79.055
Previous Close 81.21 Open 81.37
Daily Range 78.81 - 81.37 52wk Range 64.01 - 116.88
Volume 66,645 Dividend N/A
Average Vol (30d) 120,127 Yield N/A

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 1,241,510 1,097,110 807,005 656,202
Cost of Revenue 869,165 778,019 575,169 467,807
Gross Profit 372,345 319,091 231,836 188,395
Operating Expenses

Research and Development - - - -
Sales, General and Admin. 271,421 228,569 176,351 151,304
Non-Recurring Items - - - -
Other - - - -
Operating Income 100,924 90,522 55,485 37,091
Income From Continuing Operations

Add'l Income/Expense Items 75 47 28 249
Earnings Before Interest and Tax 100,999 90,569 55,513 37,340
Interest Expense 6,282 5,560 3,518 5,208
Earnings Before Tax 94,717 85,009 51,995 32,132
Income Tax 34,480 34,024 20,558 12,751
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 60,237 50,985 31,437 19,381
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 60,237 50,985 31,437 19,381
Preferred Stock and Other Adjustments (90) (90) (90) (90)
Net Income Applicable to Common Shareholders 60,147 50,895 31,347 19,291

Recent News

Jul 31, 2014 DXP Enterprises Announces 2014 Second Quarter Results
Jul 29, 2014 DXP Sets Date for 2014 Second Quarter Results Release and Conference Call

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...